Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Women Infertility – Pipeline Review, H1 2017, provides an overview of the Women Infertility (Women's Health) pipeline landscape.
Infertility is the inability to get pregnant after a year of unprotected intercourse. Female infertility can be also be caused by a number of factors, which include damage to fallopian tubes, hormonal causes, cervical causes, uterine causes, unexplained infertility. Treatment depends on the cause of infertility.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Women Infertility – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Women Infertility (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Women Infertility (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 14, 14, 1, 28, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 3 molecules, respectively.
Women Infertility (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Women Infertility (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Women Infertility (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Women Infertility (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women's Health)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Women Infertility (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
4P Therapeutics LLC
AbbVie Inc
Addex Therapeutics Ltd
AlphaMab Co Ltd
APAvadis Biotechnologies Srl
ASKA Pharmaceutical Co Ltd
Astellas Pharma Inc
Bayer AG
Dong-A Socio Holdings Co Ltd
Dongkook Pharmaceutical Co Ltd
ElexoPharm GmbH
EndoCeutics Inc
Enteris BioPharma Inc
Evotec AG
Ferring International Center SA
Forendo Pharma Ltd
Glycotope GmbH
Isifer AB
Kissei Pharmaceutical Co Ltd
Lipicard Technologies Ltd
Livzon Pharmaceutical Group Inc
Luye Pharma Group Ltd
Merck & Co Inc
Navya Biologicals Pvt Ltd
Nippon Shinyaku Co Ltd
Nora Therapeutics Inc
ObsEva SA
Ogeda SA
Orphagen Pharmaceuticals Inc
Pangen Biotech Inc.
Pantec Biosolutions AG
PharmaEssentia Corp
Philogen SpA
Repros Therapeutics Inc
Richter Gedeon Nyrt
SK Chemicals Co Ltd
Takeda Pharmaceutical Company Ltd
TocopheRx Inc
ValiRx Plc
Viramal Ltd
Zydus Cadila Healthcare Ltd
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Women Infertility – Overview 9
Women Infertility – Therapeutics Development 10
Pipeline Overview 10
Pipeline by Companies 11
Pipeline by Universities/Institutes 15
Products under Development by Companies 16
Products under Development by Universities/Institutes 20
Women Infertility – Therapeutics Assessment 21
Assessment by Target 21
Assessment by Mechanism of Action 24
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Women Infertility – Companies Involved in Therapeutics Development 31
4P Therapeutics LLC 31
AbbVie Inc 31
Addex Therapeutics Ltd 32
AlphaMab Co Ltd 32
APAvadis Biotechnologies Srl 33
ASKA Pharmaceutical Co Ltd 33
Astellas Pharma Inc 34
Bayer AG 34
Dong-A Socio Holdings Co Ltd 35
Dongkook Pharmaceutical Co Ltd 36
ElexoPharm GmbH 36
EndoCeutics Inc 37
Enteris BioPharma Inc 37
Evotec AG 38
Ferring International Center SA 38
Forendo Pharma Ltd 39
Glycotope GmbH 39
Isifer AB 40
Kissei Pharmaceutical Co Ltd 40
Lipicard Technologies Ltd 41
Livzon Pharmaceutical Group Inc 41
Luye Pharma Group Ltd 42
Merck & Co Inc 42
Navya Biologicals Pvt Ltd 43
Nippon Shinyaku Co Ltd 43
Nora Therapeutics Inc 44
ObsEva SA 44
Ogeda SA 45
Orphagen Pharmaceuticals Inc 45
Pangen Biotech Inc. 46
Pantec Biosolutions AG 46
PharmaEssentia Corp 47
Philogen SpA 47
Repros Therapeutics Inc 48
Richter Gedeon Nyrt 48
SK Chemicals Co Ltd 49
Takeda Pharmaceutical Company Ltd 49
TocopheRx Inc 50
ValiRx Plc 50
Viramal Ltd 51
Zydus Cadila Healthcare Ltd 51
Women Infertility – Drug Profiles 52
acolbifene hydrochloride + GnRH Agonist + prasterone – Drug Profile 52
ADX-68692 – Drug Profile 53
AKP-501 – Drug Profile 54
ASP-1707 – Drug Profile 55
barusiban – Drug Profile 56
BAY-1128688 – Drug Profile 57
BAY-1158061 – Drug Profile 58
Biosimilar 2 for Diabetes, Infertility and Rheumatoid Arthritis – Drug Profile 59
Biosimilar 5 for Infertility and Oncology – Drug Profile 60
Biosimilar 6 for Infertility, Oncology and Immunology – Drug Profile 61
Biosimilar 7 for Infertility, Immunology, Infectious Disease and Oncology – Drug Profile 62
choriogonadotropin alfa biosimilar – Drug Profile 63
choriogonadotropin alfa biosimilar – Drug Profile 64
danazol – Drug Profile 65
Drug 1 for Endometriosis – Drug Profile 66
Drug 2 for Endometriosis – Drug Profile 67
Drug 3 for Endometriosis – Drug Profile 68
Drug 4 for Endometriosis – Drug Profile 69
Drug 5 for Endometriosis – Drug Profile 70
Drug to Antagonize P2X3 for Endometriosis – Drug Profile 71
Drug to Inhibit C-Jun for Endometriosis – Drug Profile 72
Drug to Inhibit Interferon Gamma for Metabolic Disorders and Women's Health – Drug Profile 73
Drugs for Endometriosis and Uterine Fibroids – Drug Profile 74
EC-313 – Drug Profile 75
elagolix sodium – Drug Profile 76
EVE-104 – Drug Profile 81
FE-999310 – Drug Profile 82
fezolinetant – Drug Profile 83
follicle stimulating hormone biosimilar – Drug Profile 86
follitropin alfa biosimilar – Drug Profile 87
follitropin alfa biosimilar – Drug Profile 89
follitropin alfa biosimilar – Drug Profile 90
follitropin delta – Drug Profile 91
FP-5677 – Drug Profile 93
FSH-GEX – Drug Profile 94
goserelin biosimilar – Drug Profile 96
goserelin ER – Drug Profile 97
Isifera – Drug Profile 98
kisspeptin-54 – Drug Profile 99
KLH-2109 – Drug Profile 100
KN-015 – Drug Profile 102
leuprolide acetate – Drug Profile 103
LM-001 – Drug Profile 104
LM-002 – Drug Profile 105
LT-6121 – Drug Profile 106
menotropins – Drug Profile 107
MIA-602 – Drug Profile 108
MK-8389 – Drug Profile 109
Monoclonal Antibody Conjugate to Agonize FSH Receptor for Women Infertility – Drug Profile 110
NAV-013 – Drug Profile 111
NS-580 – Drug Profile 112
NT-100 – Drug Profile 113
OBE-001 – Drug Profile 115
PEG-FSH – Drug Profile 118
Peptide to Agonize FSH Receptor for Women Infertility – Drug Profile 119
Peptides for Endometriosis and Hepatic Tumor – Drug Profile 120
Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor – Drug Profile 121
PGL-1001 – Drug Profile 122
PGL-2001 – Drug Profile 123
progesterone – Drug Profile 124
Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome – Drug Profile 125
relugolix – Drug Profile 126
SKI-2670 – Drug Profile 129
Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health – Drug Profile 130
Small Molecules for Female Infertility – Drug Profile 131
Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology – Drug Profile 132
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis – Drug Profile 133
Small Molecules to Antagonize SF-1 for Cushing Disease, Endometriosis and Oncology – Drug Profile 134
Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis – Drug Profile 135
Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers – Drug Profile 136
Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis – Drug Profile 137
SR-16234 – Drug Profile 138
STI-2833 – Drug Profile 139
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology – Drug Profile 140
TAK-448 – Drug Profile 141
telapristone acetate – Drug Profile 143
Tetravil – Drug Profile 152
TOP-001 – Drug Profile 154
TOP-002 – Drug Profile 155
triptorelin – Drug Profile 156
triptorelin acetate ER – Drug Profile 157
triptorelin biosimilar – Drug Profile 158
VAL-201 – Drug Profile 159
VAL-301 – Drug Profile 164
vilaprisan – Drug Profile 165
VPE-001 – Drug Profile 166
VPEA-004 – Drug Profile 167
Women Infertility – Dormant Projects 168
Women Infertility – Discontinued Products 171
Women Infertility – Product Development Milestones 172
Featured News & Press Releases 172
Appendix 183
Methodology 183
Coverage 183
Secondary Research 183
Primary Research 183
Expert Panel Validation 183
Contact Us 183
Disclaimer 184
List of Tables
Number of Products under Development for Women Infertility, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Women Infertility – Pipeline by 4P Therapeutics LLC, H1 2017
Women Infertility – Pipeline by AbbVie Inc, H1 2017
Women Infertility – Pipeline by Addex Therapeutics Ltd, H1 2017
Women Infertility – Pipeline by AlphaMab Co Ltd, H1 2017
Women Infertility – Pipeline by APAvadis Biotechnologies Srl, H1 2017
Women Infertility – Pipeline by ASKA Pharmaceutical Co Ltd, H1 2017
Women Infertility – Pipeline by Astellas Pharma Inc, H1 2017
Women Infertility – Pipeline by Bayer AG, H1 2017
Women Infertility – Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
Women Infertility – Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017
Women Infertility – Pipeline by ElexoPharm GmbH, H1 2017
Women Infertility – Pipeline by EndoCeutics Inc, H1 2017
Women Infertility – Pipeline by Enteris BioPharma Inc, H1 2017
Women Infertility – Pipeline by Evotec AG, H1 2017
Women Infertility – Pipeline by Ferring International Center SA, H1 2017
Women Infertility – Pipeline by Forendo Pharma Ltd, H1 2017
Women Infertility – Pipeline by Glycotope GmbH, H1 2017
Women Infertility – Pipeline by Isifer AB, H1 2017
Women Infertility – Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
Women Infertility – Pipeline by Lipicard Technologies Ltd, H1 2017
Women Infertility – Pipeline by Livzon Pharmaceutical Group Inc, H1 2017
Women Infertility – Pipeline by Luye Pharma Group Ltd, H1 2017
Women Infertility – Pipeline by Merck & Co Inc, H1 2017
Women Infertility – Pipeline by Navya Biologicals Pvt Ltd, H1 2017
Women Infertility – Pipeline by Nippon Shinyaku Co Ltd, H1 2017
Women Infertility – Pipeline by Nora Therapeutics Inc, H1 2017
Women Infertility – Pipeline by ObsEva SA, H1 2017
Women Infertility – Pipeline by Ogeda SA, H1 2017
Women Infertility – Pipeline by Orphagen Pharmaceuticals Inc, H1 2017
Women Infertility – Pipeline by Pangen Biotech Inc., H1 2017
Women Infertility – Pipeline by Pantec Biosolutions AG, H1 2017
Women Infertility – Pipeline by PharmaEssentia Corp, H1 2017
Women Infertility – Pipeline by Philogen SpA, H1 2017
Women Infertility – Pipeline by Repros Therapeutics Inc, H1 2017
Women Infertility – Pipeline by Richter Gedeon Nyrt, H1 2017
Women Infertility – Pipeline by SK Chemicals Co Ltd, H1 2017
Women Infertility – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Women Infertility – Pipeline by TocopheRx Inc, H1 2017
Women Infertility – Pipeline by ValiRx Plc, H1 2017
Women Infertility – Pipeline by Viramal Ltd, H1 2017
Women Infertility – Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Women Infertility – Dormant Projects, H1 2017
Women Infertility – Dormant Projects, H1 2017 (Contd..1), H1 2017
Women Infertility – Dormant Projects, H1 2017 (Contd..2), H1 2017
Women Infertility – Discontinued Products, H1 2017
List of Figures
Number of Products under Development for Women Infertility, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
